Search results
Showing 661 to 675 of 723 results for impact reports
diagnosis onwards. There are indications from research literature and patient reports that these needs are currently unmet. Helping...
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.
Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)
NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Boston Keratoprosthesis Type I for corneal blindness (MIB91)
NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
Physical activity: for NHS staff, patients and carers (QS84)
This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS84Show all sections
Sections for QS84
- Quality statements
- Quality statement 1: Advice for adults during NHS Health Checks
- Quality statement 2: Advice for parents or carers as part of the Healthy Child Programme 2-year review
- Quality statement 3: Advice for parents or carers as part of the National Child Measurement Programme
- Quality statement 4: Implementing a physical activity programme for employees in NHS organisations
- Update information
- About this quality standard
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.